Madrigal Pharmaceuticals To Participate In Morgan Stanley 23Rd Annual Global Healthcare Conference

2025-09-03 08:17:10

(MENAFN- GlobeNewsWire - Nasdaq) CONSHOHOCKEN, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Morgan Stanley 23^rd Annual Global Health Care Conference on Monday, Sept. 8, 2025 at 7:45 A.M. EDT.

The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page . A replay of the webcast will be available after the event.

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit .

Investor Contact
Tina Ventura, ...

Media Contact
Christopher Frates, ...

MENAFN03092025004107003653ID1110011780

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.